secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001193125-25-132299
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks' zanidatamab wins NMPA conditional approval in China for HER2+ BTC; $20M milestone due
--------------------------------------------------------------------------------

- NMPA (China) conditionally approved zanidatamab for previously treated unresectable/metastatic HER2+ biliary tract cancer (IHC3+).
- Zymeworks receives $20M milestone from BeOne Medicines (formerly BeiGene); already received $61M in prior payments.
- Eligible for up to $144M in additional development/commercial milestones and tiered royalties up to 19.5% on net sales.
- Approval based on HERIZON-BTC-01 study showing overall survival benefit; confirmatory trials ongoing.
- Zanidatamab previously approved by FDA (Nov 2024); EMA CHMP positive opinion (Apr 2025) for same indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525132299/0001193125-25-132299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312525132299/d18018d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer